Joao A De Andrade

List of Publications by Year
in descending order

50	3,146	279487	243296
papers	citations	23 h-index	44 g-index

54	54	54	3369
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	BUILD-1: A Randomized Placebo-controlled Trial of Bosentan in Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2008, 177, 75-81.	2.5	487
2	Treatment of Idiopathic Pulmonary Fibrosis With Ambrisentan. Annals of Internal Medicine, 2013, 158, 641.	2.0	437
3	A Placebo-Controlled Randomized Trial of Warfarin in Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2012, 186, 88-95.	2.5	423
4	Randomized Trial of Acetylcysteine in Idiopathic Pulmonary Fibrosis. New England Journal of Medicine, 2014, 370, 2093-2101.	13.9	422
5	Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis. European Respiratory Review, 2017, 26, 170057.	3.0	162
6	FG-3019 anti-connective tissue growth factor monoclonal antibody: results of an open-label clinical trial in idiopathic pulmonary fibrosis. European Respiratory Journal, 2016, 47, 1481-1491.	3.1	147
7	Pleiotropic effect of the proton pump inhibitor esomeprazole leading to suppression of lung inflammation and fibrosis. Journal of Translational Medicine, 2015, 13, 249.	1.8	105
8	Resequencing Study Confirms That Host Defense and Cell Senescence Gene Variants Contribute to the Risk of Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 199-208.	2.5	90
9	Autoimmunity to Vimentin Is Associated with Outcomes of Patients with Idiopathic Pulmonary Fibrosis. Journal of Immunology, 2017, 199, 1596-1605.	0.4	76
10	Pharmacological management of progressive-fibrosing interstitial lung diseases: a review of the current evidence. European Respiratory Review, 2018, 27, 180074.	3.0	73
11	Association of Protein C and Type 1 Plasminogen Activator Inhibitor with Primary Graft Dysfunction. American Journal of Respiratory and Critical Care Medicine, 2007, 175, 69-74.	2.5	66
12	Citrullinated vimentin mediates development and progression of lung fibrosis. Science Translational Medicine, 2021, 13, .	5.8	60
13	New Insights into the Pathogenesis and Treatment of Idiopathic Pulmonary Fibrosis. Drugs, 2011, 71, 981-1001.	4.9	56
14	Alveolar epithelial disintegrity in pulmonary fibrosis. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2016, 311, L185-L191.	1.3	52
15	Predictors of death or lung transplant after a diagnosis of idiopathic pulmonary fibrosis: insights from the IPF-PRO Registry. Respiratory Research, 2019, 20, 105.	1.4	44
16	3D pulmospheres serve as a personalized and predictive multicellular model for assessment of antifibrotic drugs. JCI Insight, 2017, 2, e91377.	2.3	42
17	Patient Registries in Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 160-167.	2.5	41
18	The Idiopathic Pulmonary Fibrosis Clinical Research Network (IPFnet). Chest, 2015, 148, 1034-1042.	0.4	37

#	Article	IF	Citations
19	Role of fibroblast growth factor 23 and klotho cross talk in idiopathic pulmonary fibrosis. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2019, 317, L141-L154.	1.3	37
20	Soluble P-Selectin and the Risk of Primary Graft Dysfunction After Lung Transplantation. Chest, 2009, 136, 237-244.	0.4	34
21	Decrements of body mass index are associated with poor outcomes of idiopathic pulmonary fibrosis patients. PLoS ONE, 2019, 14, e0221905.	1.1	31
22	Oxidative Modifications of Protein Tyrosyl Residues Are Increased in Plasma of Human Subjects with Interstitial Lung Disease. American Journal of Respiratory and Critical Care Medicine, 2016, 193, 861-868.	2.5	30
23	A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF ILOPROST INHALATION IN ADULTS WITH ABNORMAL PULMONARY ARTERIAL PRESSURE AND EXERCISE LIMITATION ASSOCIATED WITH IDIOPATHIC PULMONARY FIBROSIS. Chest, 2007, 132, 633A.	0.4	25
24	Screening Strategies for Pulmonary Hypertension in Patients With Interstitial Lung Disease. Chest, 2022, 162, 145-155.	0.4	24
25	Innovative approaches to the therapy of fibrosis. Current Opinion in Rheumatology, 2009, 21, 649-655.	2.0	21
26	Idiopathic Pulmonary Fibrosis. Immunology and Allergy Clinics of North America, 2012, 32, 473-485.	0.7	15
27	Time to diagnosis of idiopathic pulmonary fibrosis in the IPF-PRO Registry. BMJ Open Respiratory Research, 2020, 7, e000567.	1.2	15
28	Hospital-Based Resource Use and Costs Among Patients With Idiopathic Pulmonary Fibrosis Enrolled in the Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) Registry. Chest, 2020, 157, 1522-1530.	0.4	14
29	The senescence-associated matricellular protein CCN1 in plasma of human subjects with idiopathic pulmonary fibrosis. Respiratory Medicine, 2020, 161, 105821.	1.3	12
30	A bundled care approach to patients with idiopathic pulmonary fibrosis improves transplant-free survival. Respiratory Medicine, 2016, 115, 33-38.	1.3	11
31	Predicting Outcome in Idiopathic Pulmonary Fibrosis: Addition of Fibrotic Score at Thin-Section CT of the Chest to Gender, Age, and Physiology Score Improves the Prediction Model. Radiology: Cardiothoracic Imaging, 2019, 1, e180029.	0.9	10
32	CHARACTERISTICS OF PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS (IPF) IN THE US: DATA FROM THE IPF-PRO REGISTRY. Chest, 2018, 154, 397A-398A.	0.4	9
33	Delphi Consensus Recommendations on Management of Dosing, Adverse Events, and Comorbidities in the Treatment of Idiopathic Pulmonary Fibrosis with Nintedanib. Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine, 2021, 15, 117954842110060.	0.5	7
34	Expert consensus on the management of adverse events and prescribing practices associated with the treatment of patients taking pirfenidone for idiopathic pulmonary fibrosis: a Delphi consensus study. BMC Pulmonary Medicine, 2020, 20, 191.	0.8	6
35	Implementation of guideline recommendations and outcomes in patients with idiopathic pulmonary fibrosis: Data from the IPF-PRO registry. Respiratory Medicine, 2021, 189, 106637.	1.3	4
36	Association of Reactive Nitrogen Species Metabolites, Myeloperoxidase, and Airway Inflammation in Lung Transplants. Journal of Investigative Medicine, 2001, 49, 166-172.	0.7	3

#	Article	IF	Citations
37	What Is in a Pattern? That Which We Call Idiopathic Pulmonary Fibrosis by Any Other Pattern Would Behave Alike!. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 10-12.	2.5	3
38	More than meets the eye: IgG4-related disease presenting as isolated interstitial lung disease. Rheumatology, 2017, 56, 1630-1631.	0.9	3
39	Development and Maintenance of a Biospecimen Repository for Clinical Samples Derived from Pulmonary Patients. Clinical and Translational Science, 2014, 7, 336-341.	1.5	2
40	Association of Circulating Proteins with Death or Lung Transplant in Patients with Idiopathic Pulmonary Fibrosis in the IPF-PRO Registry Cohort. Lung, 2022, 200, 11-18.	1.4	2
41	Impact of timing of nintedanib initiation among patients newly diagnosed with idiopathic pulmonary fibrosis. Journal of Medical Economics, 2022, 25, 532-540.	1.0	2
42	Thoughts on the Diagnosis and Management of Interstitial Lung Diseases. Southern Medical Journal, 2007, 100, 555-556.	0.3	1
43	Patient journey to diagnosis of idiopathic pulmonary fibrosis (IPF) in the US. , 2017, , .		1
44	Baseline characteristics of 1461 participants in the Pulmonary Fibrosis Foundation Patient Registry. , 2018, , .		1
45	Fatigue in patients with idiopathic pulmonary fibrosis (IPF) from the pooled pirfenidone (PFD) Phase III trials. , 2017, , .		1
46	Associations between resources and practices of ILD centers and outcomes in patients with idiopathic pulmonary fibrosis: data from the IPF-PRO Registry. Respiratory Research, 2022, 23, 3.	1.4	1
47	Testing a Simplified High Resolution CT scan Of The Chest (HRCT) Classification As Predictor Of Outcomes In Patients With Interstitial Lung Disease. , 2010, , .		0
48	The Diagnostic Approach to Interstitial Lung Disease. Current Pulmonology Reports, 2018, 7, 149-159.	0.5	0
49	Patterns of discontinuation in the long-term RECAP study of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF). , 2017, , .		0
50	Predictors of death or transplant in patients with idiopathic pulmonary fibrosis in the IPF-PRO Registry. , 2018, , .		0